PNTライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 12月 2023 @ 06:00):

Stats
本日の出来高	3.29M
平均出来高	3.85M
時価総額	1.33B
EPS	$0 ( 2024-03-25 )
次の収益日	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	11.36
ATR14	$0.322 (2.58%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-26	Goodman Jonathan R.	Sell	41 872	Common Stock
2023-12-27	Goodman Jonathan R.	Sell	35 872	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	25 000	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	25 614	Stock Option (Right to Buy)
2023-12-27	Goodman Jonathan R.	Sell	44 749	Stock Option (Right to Buy)

INSIDER POWER
-78.00
Last 96 transactions
Buy: 3 517 450 \| Sell: 10 366 533

ボリューム相関

長: 0.24 (neutral)

短: -0.64 (weak negative)

Signal:(35.382) Neutral

POINT Biopharma Global 相関

10 最も正の相関
RCM	0.813
LUNG	0.806
TTWO	0.805

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

POINT Biopharma Global 相関 - 通貨/商品

-0.48
( neutral )

0.29
( neutral )

0.58
( weak )

-0.20
( neutral )

-0.24
( neutral )

0.38
( neutral )

POINT Biopharma Global 財務諸表

Annual	2022
収益:	$226.58M
総利益:	$226.58M (100.00 %)
EPS:	$1.040

FY	2022
収益:	$226.58M
総利益:	$226.58M (100.00 %)
EPS:	$1.040

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.181

FY	2020
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.00801

Financial Reports:

No articles found.

POINT Biopharma Global

POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer; and PNT2003, a somatostatin-targeted radioligand, which is in Phase III trial for the treatment of neuroendocrine tumors. The company is also developing PNT2001, a next-generation PSMA-targeting product candidate for the treatment of non-metastatic castration sensitive prostate cancer, which is under preclinical studies; and PNT-2004, a fibroblast activation protein-a targeting program being developed for use in multiple tumor types that is under preclinical studies. In addition, it has product candidates being developed on CanSEEK technology sub-licensed from both Bach Biosciences LLC and Avacta Life Sciences Limited. POINT Biopharma Global Inc. was founded in 2019 and is headquartered in Indianapolis, Indiana.